IRIDEX Corporation (IRIX)

Currency in USD
0.4663
-0.0337(-6.74%)
Closed·
0.4756+0.0093(+1.99%)
·
Trading near 52-week Low
IRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.45000.4993
52 wk Range
0.45001.6481
Key Statistics
Prev. Close
0.4663
Open
0.4751
Day's Range
0.45-0.4993
52 wk Range
0.45-1.6481
Volume
216.9K
Average Volume (3m)
383.69K
1-Year Change
-50.3936%
Book Value / Share
-0.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.0000
Upside
+328.91%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

IRIDEX Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.0000
(+328.91% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Alliance Global Partners
Buy3.00+543.36%-New CoverageFeb 05, 2026

IRIDEX Corporation Earnings Call Summary for Q3/2026

  • IRIDEX posted Q3 2026 loss of $0.08/share vs. $0.02 estimate; revenue fell 18.4% to $10.2M, missing $12.98M forecast by 21.4%; shares plunged 25%.
  • Gross margin surged to 42.4% from 32.1% YoY on favorable mix and pricing; U.S. glaucoma revenue jumped 50%, offset by weak international retina sales.
  • Company cut FY2026 revenue guidance to $46M-$48M; Q4 revenue expected at $11.5M-$13.5M with potential adjusted EBITDA profitability at range's high end.
  • CEO Mercer expects 2027 to deliver improved margins, lower costs, and operating profits following completed manufacturing relocation to San Jose.
  • Cash declined to $3.7M from $4.7M; international headwinds persist from China/Japan weakness, European regulatory delays, and Middle East geopolitical risks.
Last Updated: 17/11/2026, 23:44
Read Full Transcript

Earnings

Latest Release
Nov 17, 2026
EPS / Forecast
-0.08 / -0.02
Revenue / Forecast
10.2M / 12.98M
EPS Revisions
Last 90 days

IRIX Income Statement

Compare IRIX to Peers and Sector

Metrics to compare
IRIX
Peers
Sector
Relationship
P/E Ratio
−2.5x−3.7x−0.2x
PEG Ratio
−0.07−0.310.00
Price/Book
−2.5x1.2x2.6x
Price / LTM Sales
0.2x1.6x2.7x
Upside (Analyst Target)
328.9%32.3%72.2%
Fair Value Upside
Unlock12.0%12.4%Unlock

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
693.57K3.95%346.78K
Other Institutional Investors
7.14M40.62%3.57M
Public Companies & Retail Investors
9.74M55.43%4.87M
Total
17.56M100.00%8.78M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Topcon Corporation9.21%1,618,122809
Xinbo Venture Capital Management Consulting Co., Ltd.6.76%1,186,809593

People Also Watch

42.51
PENG
-1.62%
0.0365
PARA
-42.16%
1.070
CMTL
-2.73%
0.7320
AMOD
-6.50%
4.290
FMC
-8.33%

FAQ

What Is the IRIDEX (IRIX) Stock Price Today?

The IRIDEX stock price today is 0.4663 USD.

What Stock Exchange Does IRIDEX Trade On?

IRIDEX is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for IRIDEX?

The stock symbol for IRIDEX is "IRIX."

What Is the IRIDEX (IRIX) Afterhours Price Today? (Afterhours variable test: 0.4756) Current Date: Nov 20, 2026

After hours price: 0.4756. After hours price change (units): 0.0093. Price change percentage: 1.9900%

What Is the IRIDEX Market Cap?

As of today, IRIDEX market cap is 8.3000M USD.

What Is IRIDEX's Earnings Per Share (TTM)?

The IRIDEX EPS (TTM) is -0.19.

When Is the Next IRIDEX Earnings Date?

IRIDEX will release its next earnings report on Apr 01, 2027.

From a Technical Analysis Perspective, Is IRIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IRIDEX Stock Split?

IRIDEX has split 0 times.

How Many Employees Does IRIDEX Have?

IRIDEX has 93 employees.

What is the current trading status of IRIDEX (IRIX)?

As of Nov 20, 2026, IRIDEX (IRIX) is trading at a price of 0.4663 USD, with a previous close of 0.4663 USD. The stock has fluctuated within a day range of 0.4500 USD to 0.4993 USD, while its 52-week range spans from 0.4500 USD to 1.6481 USD.

What Is IRIDEX (IRIX) Price Target According to Analysts?

The average 12-month price target for IRIDEX is 2.0000 USD, with a high estimate of 2 USD and a low estimate of 2 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +328.91% Upside potential.

What Is the IRIX Premarket Price?

IRIX's last pre-market stock price is 0.4810 USD. The pre-market share volume is 8,340.0000, and the stock has decreased by -0.0190, or -3.8000%.

What Is the IRIX After Hours Price?

IRIX's last after hours stock price is 0.4756 USD, the stock has decreased by 0.0093, or 1.9900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.